Golden Cross ?
It moved from Golden cross and didn't even stop at Death cross LOL
My guess, sideways a few days/week
back down to 1.20/1.25 area
bounce back up to 1.75 area
back to 1.35 area for months and months of sideways
It moved from Golden cross and didn't even stop at Death cross LOL
My guess, sideways a few days/week
back down to 1.20/1.25 area
bounce back up to 1.75 area
back to 1.35 area for months and months of sideways
Recent ATOS News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/16/2026 12:30:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/30/2026 11:22:50 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/30/2026 09:33:51 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/30/2026 09:30:46 PM
- Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update • PR Newswire (US) • 03/25/2026 09:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/25/2026 09:21:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 09:20:21 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/20/2026 08:52:24 PM
- The Patent Cliff is Coming, Driving Smart Money Towards Precision Oncology • GlobeNewswire Inc. • 03/19/2026 03:00:00 PM
- Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives • PR Newswire (US) • 03/19/2026 12:00:00 PM
- Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference • PR Newswire (US) • 03/12/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 09:22:08 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/20/2026 09:16:05 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/20/2026 09:07:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 09:30:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 01:45:24 PM
- Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook • PR Newswire (US) • 02/11/2026 01:30:00 PM
- Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program • PR Newswire (US) • 02/05/2026 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/26/2026 01:00:26 PM
- Atossa Therapeutics Receives FDA Orphan Drug Designation for (Z)-Endoxifen for the Treatment of Duchenne Muscular Dystrophy • PR Newswire (US) • 01/16/2026 09:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2026 01:15:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/06/2026 01:30:24 PM
- Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer • PR Newswire (US) • 01/06/2026 01:15:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/22/2025 01:30:27 PM
- Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category • PR Newswire (US) • 12/17/2025 01:15:00 PM
